Some information from Bell Potters...
Bell Potters Analyst outlook & stock picks for FY 22 in the healthcare sectors was Immutep,Genetic Signatures and mesoblast
(IMM)Immutep is developing immunotherapies for cancer and autoimmune diseases. It is the leader in LAG-3, which has emerged as the next big immuno-oncology checkpoint with recent validation from pivotal data on Bristol Myers Squibb’s relatlimab. Clinical data released recently at ASCO of IMM’s lead drug efti with Merck’s Keytruda in lung and head and neck cancer has increased our confidence in the asset. A $65m capital raise is ongoing to extend the cash runway to 4QCY23 and fund new trials including a Phase 3. We see the release of further clinical data as the key catalyst forthe stock in FY22, driving subsequent new collaborations and licensing/M&A interest.Buy (Speculative), Valuation $0.85
- Forums
- ASX - By Stock
- IMM
- News: IMM Immutep Receives FDA And Irb Approval In The Us For Phase Iib Tacti-003 Trial In Hnscc
News: IMM Immutep Receives FDA And Irb Approval In The Us For Phase Iib Tacti-003 Trial In Hnscc, page-4
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
30.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $450.9M |
Open | High | Low | Value | Volume |
31.5¢ | 31.8¢ | 30.5¢ | $641.8K | 2.070M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
21 | 74525 | 30.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 71367 | 11 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
21 | 74525 | 0.305 |
32 | 487012 | 0.300 |
13 | 161139 | 0.295 |
16 | 375335 | 0.290 |
12 | 1241097 | 0.285 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 71367 | 11 |
0.315 | 215821 | 15 |
0.320 | 113000 | 9 |
0.325 | 257229 | 9 |
0.330 | 70245 | 6 |
Last trade - 14.22pm 17/10/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non Executive Director
Simon Kidston
Non Executive Director
SPONSORED BY The Market Online